FDA to Assess Cardiovascular Risk Posed by Testosterone Replacement Therapy in September Meetings, Report Attorneys Handling National Androgel Lawsuit Claims

Share Article

Lawyers handling Androgel lawsuits at The Onder Law Firm provide comprehensive Androgel lawsuit news and updates at AndrogelTestosteroneLawsuitCenter.com.

James G. Onder

The FDA will convene a Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting to discuss matters related to testosterone replacement therapy, report attorneys accepting Androgel lawsuit claims.* The committee is scheduled to convene on September 17 and 18, 2014, in Hyattsville, Maryland. According to a preliminary agenda, the committee will discuss “the appropriate indicated population for testosterone replacement therapy and the potential for adverse cardiovascular outcomes associated with this use” on September 17.

Federal regulators released a warning on potential cardiovascular risks of testosterone replacement therapy on January 31, 2014.** The Drug Safety Communication implies the FDA has been monitoring the risks associated with testosterone therapies including Androgel for some time. This particular warning was issued due to two new studies indicating a connection between supplemental testosterone and a heightened risk for cardiovascular events such as stroke and heart attack. The warning states that federal regulators are continuing to assess the risk and will notify the public at a later point when an assessment has been made.

Androgel and similar testosterone replacement therapies are approved by the FDA only for use in patients with genuine hypogonadism who suffer from associated health problems, according to the January 31, 2014 Drug Safety Communication. Hypogonadism refers to low natural testosterone levels in men, and can cause a variety of health concerns. Other conditions can readily mask as hypogonadism; the only certain method of diagnosis is by blood test. The Journal of the American Medical Institute found that as many as a quarter of men taking testosterone drugs such as Androgel were never tested for hypogonadism.***

Time Magazine reported on July 31, 2014 that “the market for low-testosterone, or “Low-T,” therapy [is] projected to reach $5 billion by 2017”.**** Androgel is the most popular of more than a dozen different testosterone replacement therapy drugs.

Nationally respected for its work in product safety litigation against national and multi-national entities, The Onder Law Firm has committed its significant resources to providing legal representation for Androgel lawsuits. Persons who suffered from a heart attack or stroke while using testosterone replacement therapy may have grounds to file a testosterone lawsuit.

The Androgel Testosterone Lawsuit Center website serves as a national resource on Androgel lawsuit news and information. Persons who believe they may qualify to file an Androgel claim are eligible for a no-cost, no-obligation consultation through the website.

The Onder Law Firm welcomes AndroGel lawsuit or other testosterone case inquiries from law firms in regards to handling them or working as co-counsel.

About The Onder Law Firm
Onder, Shelton, O’Leary & Peterson, LLC is a St. Louis based personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The pharmaceutical and medical device litigators at The Onder Law Firm have represented thousands of Americans in lawsuits against multinational conglomerates from products liability for manufacture of defective or dangerous products to deceptive advertising practices. Other firms throughout the nation often seek its experience and expertise on complex litigation. It is also a recognized leader in products liability cases such as window blind cord strangulation. The Onder Law Firm offers information from attorneys handling Androgel lawsuits at http://www.AndrogelTestosteroneLawsuitCenter.com.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Gudeman
Gudeman Group
+1 (314) 614-8709
Email >
Visit website